MVT 3501
Alternative Names: MVT-3501Latest Information Update: 18 Sep 2025
At a glance
- Originator Microviable Therapeutics
- Class Anti-infectives; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Infections
Most Recent Events
- 16 Sep 2025 Preclinical trials in Infections in Spain (unspecified route) (MicroViable Therapeutics pipeline, Septemeber 2025)